Facioscapulohumeral Muscular Dystrophy clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).
Orange, California and other locations